Nisa Investment Advisors LLC Purchases 9,098 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Nisa Investment Advisors LLC lifted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 14,674.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,160 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,098 shares during the period. Nisa Investment Advisors LLC's holdings in Jazz Pharmaceuticals were worth $1,127,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Envestnet Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 900.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 514,654 shares of the specialty pharmaceutical company's stock worth $6,364,000 after purchasing an additional 463,213 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Jazz Pharmaceuticals by 558.6% during the third quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company's stock worth $41,780,000 after acquiring an additional 273,764 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 28.1% in the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company's stock valued at $125,916,000 after buying an additional 224,865 shares during the period. Bank of America Corp DE lifted its position in shares of Jazz Pharmaceuticals by 76.6% during the 1st quarter. Bank of America Corp DE now owns 504,472 shares of the specialty pharmaceutical company's stock valued at $73,819,000 after acquiring an additional 218,893 shares during the period. Finally, Thompson Siegel & Walmsley LLC grew its stake in Jazz Pharmaceuticals by 242.8% in the third quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company's stock valued at $35,023,000 after acquiring an additional 191,648 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JAZZ. HC Wainwright reduced their price objective on Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating for the company in a research note on Thursday, March 14th. Cantor Fitzgerald restated an "overweight" rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Needham & Company LLC reissued a "buy" rating and issued a $220.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Royal Bank of Canada reiterated an "outperform" rating and issued a $195.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Finally, Barclays dropped their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating on the stock in a research report on Friday, March 1st. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $195.08.

Jazz Pharmaceuticals Trading Down 1.8 %

Shares of NASDAQ JAZZ traded down $2.01 during mid-day trading on Tuesday, reaching $108.90. The company had a trading volume of 545,614 shares, compared to its average volume of 614,403. The stock has a market cap of $6.86 billion, a price-to-earnings ratio of 17.79, a price-to-earnings-growth ratio of 1.53 and a beta of 0.59. Jazz Pharmaceuticals plc has a 52 week low of $108.75 and a 52 week high of $146.70. The business's 50-day moving average is $120.99 and its 200-day moving average is $122.95. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Equities analysts expect that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CFO Philip L. Johnson purchased 12,000 shares of the business's stock in a transaction dated Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares of the company's stock, valued at approximately $3,342,063.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip L. Johnson bought 12,000 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now owns 27,932 shares of the company's stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.